Angiotensin-converting enzyme inhibitors ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ?-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study
Auteur(s) :
Ferreira, Joao Pedro [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Couchoud, Cecile [Auteur]
Agence de la biomédecine [Saint-Denis la Plaine]
Gregson, John [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Tiple, Aurelien [Auteur]
Service de Néphrologie - Hémodialyses [CHU Clermont-Ferrand]
Glowacki, Francois [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
London, Gerard [Auteur]
Centre Hospitalier Manhès [Fleury-Mérogis]
Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] [INI-CRCT]
Agarwal, Rajiv [Auteur]
Indiana University School of Medicine
Rossignol, Patrick [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Couchoud, Cecile [Auteur]
Agence de la biomédecine [Saint-Denis la Plaine]
Gregson, John [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Tiple, Aurelien [Auteur]
Service de Néphrologie - Hémodialyses [CHU Clermont-Ferrand]
Glowacki, Francois [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
London, Gerard [Auteur]
Centre Hospitalier Manhès [Fleury-Mérogis]
Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] [INI-CRCT]
Agarwal, Rajiv [Auteur]
Indiana University School of Medicine
Rossignol, Patrick [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Titre de la revue :
Nephrology, dialysis, transplantation . official publication of the European Dialysis and Transplant Association - European Renal Association
Nom court de la revue :
Nephrol. Dial. Transplant.
Numéro :
34
Pagination :
1216–1222
Éditeur :
Oxford Academic
Date de publication :
2018-12-24
ISSN :
1460-2385
Mot(s)-clé(s) :
mortality
neurohormonal blocking agents
end-stage renal disease
neurohormonal blocking agents
end-stage renal disease
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. ...
Lire la suite >Background End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. Methods Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. Results A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1–8.2] versus matched controls 9.5 (8.8–10.1) [HR 0.76 (95% CI 0.69–0.84)], β-blocker 7.1 (6.6–7.7) versus matched controls 9.5 (8.5–10.2) [HR 0.72 (0.65–0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4–6.4) versus matched controls 7.8 (7.2–8.4) [HR 0.68 (0.61–0.77)]. Conclusions Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.Lire moins >
Lire la suite >Background End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. Methods Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. Results A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1–8.2] versus matched controls 9.5 (8.8–10.1) [HR 0.76 (95% CI 0.69–0.84)], β-blocker 7.1 (6.6–7.7) versus matched controls 9.5 (8.5–10.2) [HR 0.72 (0.65–0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4–6.4) versus matched controls 7.8 (7.2–8.4) [HR 0.68 (0.61–0.77)]. Conclusions Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Institut Pasteur de Lille
Université de Lille
Institut Pasteur de Lille
Université de Lille
Date de dépôt :
2022-02-02T10:24:05Z
2024-03-13T10:18:29Z
2024-03-13T10:18:29Z